Multiple in Vivo Phosphorylated Tyrosine Phosphatase SHP-2 Engages Binding to Grb2 Via Tyrosine 584
Overview
Molecular Biology
Affiliations
SHP-2 (also named PTP1D, syp, or SH-PTP2) has been identified as a phosphotyrosine phosphatase comprising two src-homology-2 (SH2) domains. Upon growth factor stimulation, SHP-2 becomes tyrosine phosphorylated, thereby increasing its catalytic activity. Here, we identified SHP-2 to be phosphorylated on multiple tyrosine residues in response to different stimuli and unmasked the carboxyl-terminal tyrosine 584 as a major phosphorylation site in human cell lines. Tyrosine 584 shares, together with tyrosine 546, the consensus sequence pY-X-N-X, a characteristic of potential binding sites for the SH2 domain of growth factor receptor-bound protein 2 (Grb2). We show here that mutation of tyrosine 584, but not tyrosine 546, to phenylalanine totally abolished the binding of Grb2 to SHP-2. By using a systematic mutagenesis approach, phosphorylation of additional tyrosines in each of the SH2 domains of SHP-2 was detected after coexpression of epidermal growth factor receptor, but not after coexpression of platelet-derived growth factor receptor, whereas tyrosine 263 located in the interspace between SH2 and catalytic domain appears to be exclusively recognized by platelet-derived growth factor receptor. Immunoprecipitation of SHP-2 from a panel of mammary carcinoma cell lines copurifies several tyrosine phosphorylated proteins; the most prominent band has an apparent molecular weight of M(r) 115,000.
MET Signaling Pathways, Resistance Mechanisms, and Opportunities for Target Therapies.
Rivas S, Marin A, Samtani S, Gonzalez-Feliu E, Armisen R Int J Mol Sci. 2022; 23(22).
PMID: 36430388 PMC: 9697723. DOI: 10.3390/ijms232213898.
From Stem to Sternum: The Role of Shp2 in the Skeleton.
Jensen N, Kelly R, Kelly K, Khoo S, Sidles S, LaRue A Calcif Tissue Int. 2022; 112(4):403-421.
PMID: 36422682 DOI: 10.1007/s00223-022-01042-3.
Targeting SHP2 phosphatase in hematological malignancies.
Kanumuri R, Pasupuleti S, Burns S, Ramdas B, Kapur R Expert Opin Ther Targets. 2022; 26(4):319-332.
PMID: 35503226 PMC: 9239432. DOI: 10.1080/14728222.2022.2066518.
Targeting KRAS in pancreatic cancer: new drugs on the horizon.
Bannoura S, Uddin M, Nagasaka M, Fazili F, Al-Hallak M, Philip P Cancer Metastasis Rev. 2021; 40(3):819-835.
PMID: 34499267 PMC: 8556325. DOI: 10.1007/s10555-021-09990-2.
Mlakar V, Morel E, Jurkovic Mlakar S, Ansari M, Gumy-Pause F J Exp Clin Cancer Res. 2021; 40(1):189.
PMID: 34103089 PMC: 8188681. DOI: 10.1186/s13046-021-01967-x.